Table 2 Characteristics of the 70 patients included in the study
From: Association between circulating alpha-1 antitrypsin polymers and lung and liver disease
Variables | ZZ (n = 32) | Z- (n = 29) | Other (n = 9) | p value |
|---|---|---|---|---|
Age, years | 54.6 (15.4) | 50.1 (13.5) | 47 (17.6) | 0.235 |
Sex, male (%) | 20 (62.5) | 16 (55.2) | 3 (33.3) | 0.297 |
BMI (kg/m2) | 24.1 (3.2) | 24.7 (3.5) | 24.6 (4.2) | 0.683 |
Smokers (%) | 0 | 6 (20.7) | 1 (11.1) | 0.120 |
Ex-smokers (%) | 18 (58.1) | 14 (48.3) | 4 (44.4) | |
Never smokers (%) | 13 (41.9) | 9 (31) | 4 (44.4) | |
Tobacco exposure (pack-years) | 22.7 (14.6) | 32.4 (34.1) | 34 (16.7) | 0.360 |
COPD (%) | 21 (65.6) | 9 (31) | 2 (22) | 0.008 |
Charlson index | 2.2 (1.6) | 1.5 (1.3) | 1.5 (1.9) | 0.122 |
FVC (%) | 83 (27) | 100 (19) | 104 (15) | 0.014 |
FEV1 (%) | 69 (32) | 92 (31.3) | 99 (15) | 0.007 |
FEV1/FVC | 63 (16) | 71 (17) | 76 (4.8) | 0.028 |
LSM (kPa) | 5.3 (1.2) | 4.5 (1.2) | 4.4 (0.9) | 0.008 |
FIB-4 | 1.5 (0.9) | 1.1 (0.4) | 1.1 (0.6) | 0.115 |
Augmentation therapy (%) | 11 (34) | 0 | 0 | < 0.001 |
Haemoglobin (g/dL) | 15.4 (1.4) | 14.4 (1.2) | 14.2 (1.2) | 0.008 |
Leukocytes (× 109/L) | 7.6 (2.7) | 7.6.(2.8) | 7.1 (1.5) | 0.922 |
Platelets (× 109/L) | 242 (71) | 245 (54) | 282 (51) | 0.163 |
AST (IU/L) | 29.9 (12.2) | 24.4 (7.2) | 29.6 (18.9) | 0.129 |
ALT (IU/L) | 30.4 (18.1) | 25.8 (14.1) | 24.9 (13.7) | 0.392 |
ALP (IU/L) | 81.6 (25.2) | 78.6 (29.2) | 80.5 (21.5) | 0.819 |
GGT (U/L) | 32.9 (16.1) | 37.5 (51.5) | 41.8 (18.8) | 0.234 |
Proteins (g/dL) | 7.1 (0.5) | 7.3 (0.3) | 7.2 (0.5) | 0.489 |
AAT (mg/dL) | 40 (36) | 74 (25) | 82 (22) | < 0.001 |
CRP (mg/L) | 0.2 (0.2) | 0.3 (0.6) | 0.2 (0.2) | 0.261 |
Fibrinogen (g/L) | 3.7 (0.5) | 3.8 (0.8) | 3.9 (0.7) | 0.353 |
ELF | 8.7 (0.9) | 8.1 (0.7) | 8.6 (0.8) | 0.004 |
AAT polymers (µg/mL) | 37.4 (16.4) | 13.5 (8) | 2.3 (2.9) | < 0.001 |
AAT polymers, % | 12.8 (7.2) | 2.2 (2) | 0.3 (0.5) | < 0.001 |